Efungumab and caspofungin: Pre-clinical data supporting synergy

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 5, 2008, Pages 1132-1139

  Hodgetts, Samantha ^a   Nooney, Lucy ^a   Al Akeel, Raid ^b   Curry, Alan ^c   Awad, Sawsan ^a   Matthews, Ruth ^a,b   Burnie, James ^a,b  

^a NeuTec Pharma Ltd   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Antibodies; Combination therapies; Echinocandins; Hsp90; Yeasts

Indexed keywords

BUFFER; CASPOFUNGIN; EFUNGUMAB; FLUCONAZOLE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; MYCOGRAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; COLONY FORMATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; ELECTRON MICROSCOPY; FEMALE; FUNGAL STRAIN; FUNGUS GROWTH; INVASIVE CANDIDIASIS; KIDNEY; KIDNEY BIOPSY; LIVER; LIVER BIOPSY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; RISK REDUCTION; SPLEEN; SPLEEN BIOPSY; STATISTICAL SIGNIFICANCE; UPREGULATION; YEAST;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ECHINOCANDINS; FEMALE; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; MICE; MICROBIAL SENSITIVITY TESTS; SPECIES SPECIFICITY;

EID: 42149195969     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn075     Document Type: Article

References (36)

1. Fridkin SK. Candidemia is costly - plain and simple. Clin Infect Dis 2005; 41: 1240-1.
2. Kontoyiannis DP, Lewis RE. Toward more effective antifungal therapy: The prospects of combination therapy. Br J Haematol 2004; 126: 165-75.
3. Brown AJ, Odds FC, Gow NA. Infection-related gene expression in Candida albicans. Curr Opin Microbiol 2007; 10: 307-13.
4. Hube B. Infection-associated genes of Candida albicans. Future Microbiol 2006; 1: 209-18.
5. Matthews RC, Burnie JP, Tabaqchali S. Immunoblot analysis of the serological response in systemic candidosis. Lancet 1984; 11 1415-8.
6. Matthews RC, Burnie JP, Tabaqchali S. Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to Candida albicans. J Clin Microbiol 1987; 25: 230-7.
7. Matthews RC, Rigg G, Hodgetts S et al. Preclinical assessment of the efficacy of Mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother 2003; 47: 2208-16.
8. Picard D. Hsp90 invades the outside. Nat Cell Biol 2004; 6: 479-80.
9. Burnie JP, Carter TL, Hodgetts SJ et al. Fungal heal-shock proteins in human disease. FEMS Microbiol Rev 2006; 30: 53-88.
10. Jin S, Song YC, Emili A et al. JIpA of Campylobacter jejuni interacts with surface-exposed heat shock protein 90α and triggers signalling pathways leading to the activation of NF-KB and p38 MAP kinase in epithelial cells. Cell Microbiol 2003; 5: 165-74.
11. Reyes-Dal Valle J, Chavez-Salinas S, Medina F et al. Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. J Virol 2005; 79: 4557-67.
12. Eustace BK, Sakurai T, Stewart JK et al. Functional proteomic screens reveal an essential extracellular role for hsp90α in cancer cell invasiveness. Nat Cell Biol 2004; 6: 507-14.
13. Tsutsumi S, Neckers L. Extracellular heat shock protein 90: A role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci 2007; 98: 1536-9.
14. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: Drug resistance in diverse fungi. Science 2005; 309: 2185-9.
15. Heitman J. Cell biology. A fungal Achilles' heel. Science 2005; 309: 2175-6.
16. Nooney L, Matthews RC, Burnie JP. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn Microbiol Infect Dis 2005; 51: 19-29.
17. Pachl J, Svoboda P, Jacobs F et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006; 42 1404-13.
18. Falagas ME, Ntziora F, Betsi GI et al. Caspofungin for the treatment of fungal infections: A systematic review of randomized controlled trials. Int J Antimicrob Agents 2007; 29: 136-43.
19. Baixench MT, Aoun N, Desnos-Ollivier M et al. Acquired resistance to echinocandins in Candida albicans: Case report and review. J Antimicrob Chemother 2007; 59: 1076-83.
20. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts - Secand Edition: Approved Standard M27-A2. NCCLS, Wayne, PA, USA, 2002.
21. Pfaller MA, Boyken L, Hollis RJ et al. Global surveillance of in vitro activity of micafungin against Candida: A comparison with caspofungin by CLSI-recommended methods. J Clin Microbiol 2006; 44: 3533-8.
22. Klepser ME, Ernst EJ, Ernst ME et al. Evaluation of endpoints for antifungal susceptibility determinations with LY303366. Antimicrob Agents Chemother 1998; 42: 1387-91.
23. Burnie JP, Odds FC, Lee W et al. Outbreak of systemic Candida albicans in intensive care unit caused by cross infection. Br Med J (Clin Res Ed) 1985; 290: 746-8.
24. Mata-Essayag S, Burnie J, Bailey G et al. Genotyping fluconazole resistant Candida albicans from human immunodeficiency virus positive patients. Opportunistic Pathogens 1997; 9: 27-37.
25. Essayag SM, Baily GG, Denning DW et al. Karyotyping of fluconazole-resistant yeasts with phenotype reported as Candida krusei or Candida inconspicua. Int J Syst Bacteriol 1996; 46 35-40.
26. Raska M, Belakova J, Wudattu NK et al. Comparison of protective effect of protein and DNA vaccines hsp90 in murine model of systemic candidiasis. Folia Microbiol 2005; 50: 77-82.
27. Yang Q, Wang L, Lu DN et al. Prophylactic vaccination with phage-displayed epitope of C. albicans elicits protective immune responses against systemic candidiasis in C57BL/6. mice. Vaccine 2005; 23: 4088-96.
28. Wang G, Sun M, Fang J et al. Protective immune responses against systemic candidiasis mediated by phage-displayed specific epitope of Candida albicans heat shock protein 90 in C57BL/6J mice. Vaccine 2006; 24: 6065-73.
29. Rowlands HE, Morris K, Graham C. Human recombinant antibody against Candida. Pediatr lnfect Dis J 2006; 25:_959-60.
30. Agarwal AK, Rogers PD, Baerson SR et al. Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae. J Biol Chem 2003; 278: 34998-5015.
31. Liu TT, Lee RE, Barker KS et al. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob Agents Chemother 2005; 49: 2226-36.
32. Enjalbert B, Nantel A, Whiteway M. Stress-induced gene expression in Candida albicans: Absence of a general stress response. Mol Biol Cell 2003; 14: 1460-7.
33. Enjalbert B, Smith DA, Cornell MJ et al. Role of the Hog1 stress-activated protein kinase in the global transcriptional response to stress in the fungal pathogen Candida albicans. Mol Biol Cell 2006; 17: 1018-32.
34. Cowen LE, Carpenter AE, Matangkasombut O et al. Genetic architecture of Hsp90-dependent drug resistance. Eukaryot Cell 2006; 5: 2184-8.
35. Cao YY, Cao YB, Xu Z et al. cDNA microarray analysis of differential gene expression in Candida albicans biofilm exposed to farnesol. Antimicrob Agents Chemother 2005; 49: 584-9.
36. Chandra J, Kuhn DM, Mukherjee PK et al. Biofilm formation by the fungal pathogen Candida albicans: Development, architecture, and drug resistance. J Bacteriol 2001; 183: 5385-94.